#INDIA-EU, #December 2017

The civil aviation sector was at the heart of the bond between India and the European Union (EU) in recent weeks.

India clears aviation MoU with Poland

The Union Cabinet of India, chaired by the Prime Minister Narendra Modi, has given its approval for signing the memorandum of understanding (MoU) between India and Poland for the Promotion of Civil Aviation Cooperation. The MoU, which will be for a term of five years, will be signed on behalf of the two countries after its approval by the two governments.

The objective of the MoU is to recognise the mutual benefit of Cooperation in the field of civil aviation, having particular significance in establishing and improving Regional Air Connectivity in India. Apart from this, both sides will recognise the mutual benefits of environmental testing or approvals, flight simulators monitoring and approvals, aircraft maintenance facilities approvals, maintenance personnel approvals and aircrew members’ approvals.

This MoU will promote and facilitate mutual cooperation by providing support in the civil aviation market by reviewing any legal and procedural issues which may adversely affect cooperation between India and Poland.

It also looks at promoting exchange of information and expertise between the Ministries and respective civil aviation authorities related to aviation regulations, regional air operations, airworthiness requirements and safety standards to enhance safety and security of air transport, among other things.

#India-UK, #2016, #October 2016

Beats Mylan, Novartis, Torrent, Aurobindo to the post. Promoter says hungry for more

Almost inarguably, October 5th 2016, a Wednesday was the biggest day in the life of 53 year old Binish Hasmukh Chudgar, the highly low profile vice chairman of Ahmedabad based Intas Pharmaceuticals. That day in central London, Intas snapped up Israeli generic drug maker Teva’s assets in UK and Ireland—Actavis UK Ltd and Actavis Ireland Ltd—in a record $ 764 million deal (Rs 5083 crore) out muscling bigger global rivals like Mylan and Novartis or domestic competition like Aurobindo pharma and Torrent Pharmaceuticals in a bidding process that lasted over 6 months.